Scroll

mupirocin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
aminoacyl-tRNA synthetase inhibitors	1857	12650-69-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mupirocin mupricin pseudomonic acid turixin mupirocin calcium bactroban BRL 4910A	A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing. Molecular weight: 500.63 Formula: C26H44O9 CLOGP: 1.54 LIPINSKI: 1 HAC: 9 HDO: 4 TPSA: 146.05 ALOGS: -4.28 ROTB: 17 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mupirocin
mupricin
pseudomonic acid
turixin
mupirocin calcium
bactroban
BRL 4910A

A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.

Molecular weight: 500.63
Formula: C26H44O9
CLOGP: 1.54
LIPINSKI: 1
HAC: 9
HDO: 4
TPSA: 146.05
ALOGS: -4.28
ROTB: 17

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Dec. 31, 1987	FDA	GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	909.74	15.61	289	11937	24087	63452709
Chronic sinusitis	214.87	15.61	84	12142	12759	63464037
Paraesthesia oral	157.46	15.61	76	12150	19180	63457616
Procedural pain	152.20	15.61	77	12149	21492	63455304
Vaginal flatulence	102.06	15.61	34	12192	3259	63473537
Dyspepsia	89.11	15.61	104	12122	102092	63374704
Therapeutic product effect incomplete	87.65	15.61	114	12112	124942	63351854
Drug ineffective	85.63	15.61	411	11815	1044354	62432442
Proctitis	85.40	15.61	34	12192	5407	63471389
Female genital tract fistula	74.63	15.61	34	12192	7525	63469271
Radiculopathy	73.44	15.61	35	12191	8576	63468220
Vaginal discharge	71.25	15.61	35	12191	9163	63467633
Weight decreased	62.04	15.61	153	12073	276645	63200151
Colitis ulcerative	58.75	15.61	45	12181	26046	63450750
Colitis	55.51	15.61	57	12169	48471	63428325
Oral candidiasis	50.62	15.61	39	12187	22759	63454037
Frequent bowel movements	43.87	15.61	36	12190	22986	63453810
Hyperchlorhydria	41.52	15.61	15	12211	1829	63474967
Folate deficiency	37.22	15.61	15	12211	2460	63474336
Nasal vestibulitis	36.54	15.61	6	12220	20	63476776
Toxicity to various agents	36.40	15.61	3	12223	247247	63229549
Staphylococcal infection	32.64	15.61	40	12186	41216	63435580
Pyrexia	32.45	15.61	177	12049	470301	63006495
Purpura senile	30.88	15.61	9	12217	554	63476242
Tarsal tunnel syndrome	26.37	15.61	8	12218	566	63476230
Malaise	25.69	15.61	152	12074	415802	63060994
Erythema	25.40	15.61	83	12143	175668	63301128
Drug intolerance	25.28	15.61	14	12212	308647	63168149
Dermatitis atopic	24.62	15.61	18	12208	9706	63467090
Odynophagia	23.96	15.61	16	12210	7470	63469326
General physical health deterioration	23.59	15.61	5	12221	201397	63275399
Product dose omission issue	23.25	15.61	98	12128	234215	63242581
Rectal haemorrhage	23.01	15.61	37	12189	48993	63427803
Systemic lupus erythematosus	22.86	15.61	6	12220	208912	63267884
Humidity intolerance	20.80	15.61	6	12220	356	63476440
Sinusitis	20.34	15.61	92	12134	226561	63250235
Therapeutic product effect decreased	20.29	15.61	6	12220	193181	63283615
Resorption bone increased	20.12	15.61	8	12218	1266	63475530
Nausea	19.42	15.61	250	11976	854221	62622575
Vestibular disorder	19.23	15.61	8	12218	1423	63475373
Hospitalisation	18.95	15.61	47	12179	85034	63391762
Haematochezia	18.11	15.61	35	12191	53509	63423287
Cellulitis	17.97	15.61	45	12181	81913	63394883
Therapy interrupted	17.33	15.61	26	12200	32429	63444367
Bronchial oedema	17.17	15.61	4	12222	101	63476695
Skin exfoliation	16.87	15.61	30	12196	43072	63433724
Dry skin	16.63	15.61	35	12191	56852	63419944
Maternal exposure during pregnancy	16.58	15.61	11	12215	220051	63256745
Skin infection	16.03	15.61	17	12209	14985	63461811
Dermatitis	16.00	15.61	18	12208	16940	63459856

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis atopic	67.17	17.80	27	5556	5320	34946028
Nasal vestibulitis	52.22	17.80	8	5575	19	34951329
Food aversion	39.91	17.80	10	5573	419	34950929
Product use in unapproved indication	38.53	17.80	68	5515	117431	34833917
Staphylococcal infection	31.25	17.80	32	5551	32728	34918620
Toxic epidermal necrolysis	29.96	17.80	26	5557	21620	34929728
Pruritus	27.36	17.80	66	5517	141915	34809433
Burkholderia test positive	27.25	17.80	9	5574	1014	34950334
Pain of skin	26.98	17.80	15	5568	6094	34945254
Skin fissures	26.25	17.80	14	5569	5245	34946103
Cheilitis	23.04	17.80	10	5573	2381	34948967
Dry skin	21.92	17.80	26	5557	31261	34920087
Skin exfoliation	21.23	17.80	24	5559	27408	34923940
Skin discolouration	19.92	17.80	19	5564	17826	34933522
Cellulitis	19.09	17.80	32	5551	52919	34898429
Product dose omission issue	18.25	17.80	51	5532	119660	34831688

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	201.03	14.32	76	14356	11220	79718736
Chronic sinusitis	201	14.32	79	14353	12947	79717009
Procedural pain	160.56	14.32	80	14352	23004	79706952
Paraesthesia oral	151.46	14.32	74	14358	20397	79709559
Vaginal flatulence	108.08	14.32	33	14399	2542	79727414
Dyspepsia	85.79	14.32	102	14330	108585	79621371
Proctitis	81.93	14.32	34	14398	6398	79723558
Female genital tract fistula	80.92	14.32	33	14399	5942	79724014
Vaginal discharge	77.06	14.32	34	14398	7429	79722527
Radiculopathy	74.69	14.32	35	14397	8789	79721167
Therapeutic product effect incomplete	74.64	14.32	109	14323	141536	79588420
Weight decreased	63.97	14.32	174	14258	355024	79374932
Dermatitis atopic	55.92	14.32	30	14402	10026	79719930
Colitis ulcerative	51.89	14.32	46	14386	34696	79695260
Oral candidiasis	45.79	14.32	40	14392	29588	79700368
Colitis	45.41	14.32	61	14371	73246	79656710
Toxicity to various agents	42.24	14.32	12	14420	421528	79308428
Frequent bowel movements	39.96	14.32	37	14395	29502	79700454
Hyperchlorhydria	37.01	14.32	14	14418	2065	79727891
Folate deficiency	30.53	14.32	14	14418	3346	79726610
Food aversion	29.70	14.32	10	14422	1053	79728903
Cellulitis	27.63	14.32	61	14371	108999	79620957
Purpura senile	27.49	14.32	8	14424	522	79729434
Tarsal tunnel syndrome	27.40	14.32	8	14424	528	79729428
Product dose omission issue	26.84	14.32	102	14330	247435	79482521
Staphylococcal infection	23.89	14.32	40	14392	58255	79671701
Erythema	23.37	14.32	91	14341	223199	79506757
Resorption bone increased	22.93	14.32	9	14423	1466	79728490
Pyrexia	21.04	14.32	201	14231	678508	79051448
Odynophagia	21.02	14.32	17	14415	11310	79718646
Malaise	20.97	14.32	156	14276	489713	79240243
Dry skin	20.68	14.32	41	14391	67954	79662002
Drug interaction	20.59	14.32	27	14405	415156	79314800
Humidity intolerance	20.48	14.32	6	14426	401	79729555
Rectal haemorrhage	19.68	14.32	43	14389	76257	79653699
Skin exfoliation	18.94	14.32	35	14397	55065	79674891
Skin fissures	18.90	14.32	17	14415	13056	79716900
Skin cancer	18.73	14.32	18	14414	15022	79714934
Product use in unapproved indication	18.55	14.32	92	14340	250267	79479689
Knee operation	18.17	14.32	12	14420	5854	79724102
Drug intolerance	17.92	14.32	13	14419	264106	79465850
Bronchial oedema	17.86	14.32	4	14428	90	79729866
Skin infection	17.56	14.32	19	14413	18226	79711730
Nausea	17.45	14.32	256	14176	956940	78773016
Infusion related reaction	17.33	14.32	85	14347	230152	79499804
Pain of skin	17.28	14.32	17	14415	14596	79715360
Dermatitis contact	17.25	14.32	15	14417	11018	79718938
Steroid withdrawal syndrome	17.10	14.32	6	14426	715	79729241
Skin discolouration	16.60	14.32	28	14404	41006	79688950
Toxic epidermal necrolysis	16.19	14.32	29	14403	44552	79685404
General physical health deterioration	15.68	14.32	16	14416	275222	79454734
Vestibular disorder	15.57	14.32	8	14424	2447	79727509
Surgery	15.49	14.32	24	14408	32742	79697214
Pruritus	15.37	14.32	123	14309	394525	79335431
Otitis externa fungal	14.54	14.32	3	14429	45	79729911

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D06AX09	DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE ANTIBIOTICS FOR TOPICAL USE Other antibiotics for topical use
ATC	R01AX06	RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Other nasal preparations
FDA EPC	N0000175515	RNA Synthetase Inhibitor Antibacterial
FDA MoA	N0000175516	RNA Synthetase Inhibitors
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:48001	protein synthesis inhibitors
CHEBI has role	CHEBI:35441	antiinfective agents
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011500	Protein Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Impetigo	indication	48277006	DOID:8504
Staph Aureus Traumatic Skin Lesion Infection	indication
Methicillin-Resistant Staphylococcus Aureus Nasal Colonization	indication
Traumatic Skin Lesion Streptococcus Pyogenes Infection	indication
Folliculitis	off-label use	13600006	DOID:4409
Atopic dermatitis	off-label use	24079001	DOID:3310
Eczema	off-label use	43116000
Epidermolysis bullosa	off-label use	61003004	DOID:2730
Ecthyma	off-label use	85791004
Furunculosis	off-label use	112650006
Minor Bacterial Skin Infections	off-label use
Skin irritation	contraindication	367466007

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Bacterial infections of the skin caused by strains of Staphylococcus aureus	Indication
Dogs	Bacterial infections of the skin caused by Staphylococcus intermedius	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Bactoderm Ointment	Zoetis Inc.	1
Muricin	Fougera Pharmaceuticals Inc.	1
Mupirocin Ointment USP, 2%	Taro Pharmaceuticals U.S.A. Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.76	acidic
pKa2	12.42	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Isoleucine--tRNA ligase, cytoplasmic	Enzyme	P41252	SYIC_HUMAN		IC50	9.10	CHEMBL
Isoleucine--tRNA ligase	Enzyme		SYI1_STAAU	INHIBITOR			DRUGBANK	CHEMBL
Isoleucine--tRNA ligase	Enzyme		SYI_STRP1	INHIBITOR			CHEMBL	CHEMBL
Isoleucine--tRNA ligase	Enzyme		SYI_ECOLI		Ki	8.60	CHEMBL
Isoleucine--tRNA ligase	Enzyme		SYI_THET8		Ki	7.22	CHEMBL
Isoleucine--tRNA ligase, putative, EC 6.1.1.5	Unclassified		Q8I5G6_PLAF7		IC50	7.24	IUPHAR

External reference:

ID	Source
4019345	VUID
N0000147519	NUI
D01076	KEGG_DRUG
115074-43-6	SECONDARY_CAS_RN
4019345	VANDF
4021018	VANDF
C0085259	UMLSCUI
CHEBI:7025	CHEBI
MRC	PDB_CHEM_ID
CHEMBL3989715	ChEMBL_ID
CHEMBL2068726	ChEMBL_ID
CHEMBL719	ChEMBL_ID
D016712	MESH_DESCRIPTOR_UI
DB00410	DRUGBANK_ID
10916	IUPHAR_LIGAND_ID
5276	INN_ID
D0GX863OA5	UNII
446596	PUBCHEM_CID
221128	RXNORM
198973	MMSL
47751	MMSL
5138	MMSL
5139	MMSL
720	MMSL
002802	NDDF
005869	NDDF
387397004	SNOMEDCT_US
441528009	SNOMEDCT_US
71453003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1010	OINTMENT	20 mg	TOPICAL	ANDA	23 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1010	OINTMENT	20 mg	TOPICAL	ANDA	23 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0352	OINTMENT	20 mg	TOPICAL	ANDA	23 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7284	OINTMENT	20 mg	TOPICAL	ANDA	25 sections
BACTROBAN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-028	CREAM	20 mg	TOPICAL	NDA	22 sections
MUPIROCIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-158	OINTMENT	20 mg	TOPICAL	ANDA	16 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	16714-055	CREAM	20 mg	TOPICAL	ANDA	28 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0112	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	21695-188	OINTMENT	20 mg	TOPICAL	ANDA	19 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	21922-029	CREAM	2 g	TOPICAL	ANDA	23 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	42254-137	OINTMENT	20 mg	TOPICAL	ANDA	19 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	42254-229	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
CENTANY	HUMAN PRESCRIPTION DRUG LABEL	1	43538-300	OINTMENT	20 mg	TOPICAL	NDA	26 sections
Centany AT	HUMAN PRESCRIPTION DRUG LABEL	1	43538-310	OINTMENT	20 mg	TOPICAL	NDA	26 sections
MUPIROCIN	HUMAN PRESCRIPTION DRUG LABEL	1	45802-018	CREAM	20 mg	TOPICAL	ANDA	25 sections
MUPIROCIN	HUMAN PRESCRIPTION DRUG LABEL	1	45802-018	CREAM	20 mg	TOPICAL	ANDA	25 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	45802-112	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	45802-112	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	45865-722	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	49999-644	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	49999-644	OINTMENT	20 mg	TOPICAL	ANDA	20 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1587	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1587	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4349	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4397	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50268-568	OINTMENT	20 mg	TOPICAL	ANDA	25 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50436-0025	OINTMENT	20 mg	TOPICAL	ANDA	23 sections
mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50436-0112	OINTMENT	20 mg	TOPICAL	ANDA	24 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50436-0180	OINTMENT	20 mg	TOPICAL	ANDA	22 sections
Mupirocin	HUMAN PRESCRIPTION DRUG LABEL	1	50436-1010	OINTMENT	20 mg	TOPICAL	ANDA	23 sections